- Home
- HCWB vs PAVM Comparison
HCWB vs PAVM Comparison
Compare HCWB & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- PAVM
- Stock Information
- Founded
- HCWB 2018
- PAVM 2014
- Country
- HCWB United States
- PAVM United States
- Employees
- HCWB N/A
- PAVM N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- HCWB Health Care
- PAVM Health Care
- Exchange
- HCWB Nasdaq
- PAVM Nasdaq
- Market Cap
- HCWB 8.4M
- PAVM 9.4M
- IPO Year
- HCWB 2021
- PAVM 2016
- Fundamental
- Price
- HCWB $3.89
- PAVM $0.43
- Analyst Decision
- HCWB Strong Buy
- PAVM Strong Buy
- Analyst Count
- HCWB 1
- PAVM 1
- Target Price
- HCWB $35.00
- PAVM $20.00
- AVG Volume (30 Days)
- HCWB 94.5K
- PAVM 738.1K
- Earning Date
- HCWB 11-13-2025
- PAVM 11-12-2025
- Dividend Yield
- HCWB N/A
- PAVM N/A
- EPS Growth
- HCWB N/A
- PAVM N/A
- EPS
- HCWB N/A
- PAVM 0.83
- Revenue
- HCWB $832,841.00
- PAVM $1,020,000.00
- Revenue This Year
- HCWB $178.64
- PAVM N/A
- Revenue Next Year
- HCWB N/A
- PAVM $234.47
- P/E Ratio
- HCWB N/A
- PAVM $0.52
- Revenue Growth
- HCWB N/A
- PAVM N/A
- 52 Week Low
- HCWB $2.77
- PAVM $0.30
- 52 Week High
- HCWB $100.80
- PAVM $1.25
- Technical
- Relative Strength Index (RSI)
- HCWB 45.35
- PAVM 44.31
- Support Level
- HCWB $4.00
- PAVM $0.40
- Resistance Level
- HCWB $4.07
- PAVM $0.48
- Average True Range (ATR)
- HCWB 0.22
- PAVM 0.06
- MACD
- HCWB -0.02
- PAVM -0.01
- Stochastic Oscillator
- HCWB 4.76
- PAVM 19.15
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.